<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2072-0351-6199</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-6199</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Функциональная активность тромбоцитов при сахарном диабете 2 типа в процессе лечения препаратами сульфонилмочевины</article-title><trans-title-group xml:lang="en"><trans-title>Funktsional'naya aktivnost' trombotsitov pri sakharnom diabete 2 tipa v protsesse lecheniya preparatami sul'fonilmocheviny</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волковой</surname><given-names>А К</given-names></name><name name-style="western" xml:lang="en"><surname>Volkovoy</surname><given-names>A K</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Недосугова</surname><given-names>Людмила Викторовна</given-names></name><name name-style="western" xml:lang="en"><surname>Nedosugova</surname><given-names>Lyudmila Viktorovna</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рудько</surname><given-names>И А</given-names></name><name name-style="western" xml:lang="en"><surname>Rud'ko</surname><given-names>I A</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кубатиев</surname><given-names>А А</given-names></name><name name-style="western" xml:lang="en"><surname>Kubatiev</surname><given-names>A A</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балаболкин</surname><given-names>Михаил Иванович</given-names></name><name name-style="western" xml:lang="en"><surname>Balabolkin</surname><given-names>Mikhail Ivanovich</given-names></name></name-alternatives><email xlink:type="simple">-</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Московская медицинская академия им. И.М. Сеченова, Москва</institution></aff><aff xml:lang="ru" id="aff-2"><institution>РМАПО МЗ РФ, Москва</institution></aff><pub-date pub-type="collection"><year>2000</year></pub-date><pub-date pub-type="epub"><day>15</day><month>09</month><year>2000</year></pub-date><volume>3</volume><issue>3</issue><issue-title>№3 (2000)</issue-title><fpage>23</fpage><lpage>28</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Волковой А.К., Недосугова Л.В., Рудько И.А., Кубатиев А.А., Балаболкин М.И., 2000</copyright-statement><copyright-year>2000</copyright-year><copyright-holder xml:lang="ru">Волковой А.К., Недосугова Л.В., Рудько И.А., Кубатиев А.А., Балаболкин М.И.</copyright-holder><copyright-holder xml:lang="en">Volkovoy A.K., Nedosugova L.V., Rud'ko I.A., Kubatiev A.A., Balabolkin M.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/6199">https://www.dia-endojournals.ru/jour/article/view/6199</self-uri><abstract><p>Актуальность Специфические сосудистые осложнения, или микроангиопатий, развиваются при СД 2 типа наряду с ускоренным прогрессированием атеросклероза, что сопровождается повышенным риском тромбозов, нарушения кровообращения и внезапной смерти. Основные причины этих острых ситуаций при СД 2 типа ? это ослабление эндотелийзависимой релаксации, изменение сократимости гладкомышечной сосудистой стенки  и повышение функциональной активности тромбоцитов. Цель Сравнить влияние на окислительный стресс и функциональную активность тромбоцитов двух производных сульфонилмочевины: глибенкламида и гликлазида. Материалы и методы В 1-ю группу (8 чел.) вошли больные, получавшие на момент включения в исследование диабетон в суточной дозе от 120 до 240 мг. Во 2-ю группу (8 человек) были включены больные, получавшие на момент начала исследования Манинил??5 в суточной дозе 10-15 мг. Определяли уровень HbA1c, агрегацию тромбоцитов, липиды сыворотки, цитоплазматический Са, активность процессов перекисного окисления липидов (ПОЛ) определяли спектрофотометрическим методом, исследовали синтез тромбоцитарного сосудосуживающего фактора ? тромбоксана. Результаты Достижение компенсации углеводного обмена сопровождалось достоверным снижением HbAlc. При этом отмечалась и тенденция к снижению гипер- и дислипидемии. При достижении компенсации углеводного обмена получено достоверное снижение базального и индуцированного МДА. Функциональная активность тробоцитов также менялась, что проявилось достоверным снижением амплитуды агрегации тромбоцитов на тромбин и коллаген в обеих группах, тенденцией к снижению агрегации на АДФ в 1-й группе по сравнению с достоверным снижением агрегации на АДФ во 2-й группе больных. Уровень цитоплазматического кальция, как базального, так и стимулированного тромбином и АДФ, также достоверно снижался в обеих группах, равно как и концентрация тромбоксана В2. Выводы Проведенный сравнительный анализ не выявил преимуществ гликлазида перед глибенкламидом в отношении коррекции реоваскулярных изменений, развивающихся на фоне окислительного стресса. Отсутствие компенсации углеводного обмена вызывает прогрессирование гемореологических нарушений, являющихся основной причиной формирования диабетических ангиопатий, вне зависимости от вида получаемой сахароснижающей терапии.</p></abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>Диабетон</kwd><kwd>Манинил</kwd><kwd>диабетиченские ангиопатии</kwd><kwd>тромбоксан В2</kwd><kwd>функциональная активность тромбоцитов</kwd><kwd>эндотелийзависимая релаксация</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Акапита J., Kosaka К. et al. Long term comparation of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs other sulphonil- ureas. Diabetes Res Clin Pract. 1988, v. 5, p. 81-90.</mixed-citation><mixed-citation xml:lang="en">Акапита J., Kosaka К. et al. Long term comparation of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs other sulphonil- ureas. Diabetes Res Clin Pract. 1988, v. 5, p. 81-90.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Baba S., Nakagawa S. et al. Comparison of gliclazide and glibenclamide treatment in non- insulin-dependent diabetes. J. Exp Med 1983, Dec 141,Suppl 693-706.</mixed-citation><mixed-citation xml:lang="en">Baba S., Nakagawa S. et al. Comparison of gliclazide and glibenclamide treatment in non- insulin-dependent diabetes. J. Exp Med 1983, Dec 141,Suppl 693-706.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Baynes J. W. Perspectives in diabetes. Role of oxidative stress in development of complications in diabetes. Diabetes, 1 991,v. 40, p. 405-41 2.</mixed-citation><mixed-citation xml:lang="en">Baynes J. W. Perspectives in diabetes. Role of oxidative stress in development of complications in diabetes. Diabetes, 1 991,v. 40, p. 405-41 2.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Beck-Nielsen H., Hother-Hielsen O., Pedersen O. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet Med 1988, v. 5, p. 613-620.</mixed-citation><mixed-citation xml:lang="en">Beck-Nielsen H., Hother-Hielsen O., Pedersen O. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet Med 1988, v. 5, p. 613-620.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen R. Dysfunction of vascular endotelium in diabetes mellitus. Circulation 1993, v.87(Suppl V), V67-V76.</mixed-citation><mixed-citation xml:lang="en">Cohen R. Dysfunction of vascular endotelium in diabetes mellitus. Circulation 1993, v.87(Suppl V), V67-V76.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hattori Y., Kawasaki H. et al. Attenuated contractile response of diabetic rat aorta to caffeine but not to noradrenaline in Ca2+ -free medium. Eur J Pharmacol. 1994, v. 256, p. 215-219.</mixed-citation><mixed-citation xml:lang="en">Hattori Y., Kawasaki H. et al. Attenuated contractile response of diabetic rat aorta to caffeine but not to noradrenaline in Ca2+ -free medium. Eur J Pharmacol. 1994, v. 256, p. 215-219.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Heemskerk J. W. М., Sage S. O. Calcium signalling in platelets and other cells. Platelets 1994, v. 5, p. 295-316.</mixed-citation><mixed-citation xml:lang="en">Heemskerk J. W. М., Sage S. O. Calcium signalling in platelets and other cells. Platelets 1994, v. 5, p. 295-316.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ishii H., Umeda F., Hachimoto Т., Nawata H. Changes in phosphoinositi- dine turnover Ca2+ mobilization and protein phosphorilation in platelets from NIDDM patients. Diabetes, 1990, v. 39, p. 1562-1568.</mixed-citation><mixed-citation xml:lang="en">Ishii H., Umeda F., Hachimoto Т., Nawata H. Changes in phosphoinositi- dine turnover Ca2+ mobilization and protein phosphorilation in platelets from NIDDM patients. Diabetes, 1990, v. 39, p. 1562-1568.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jennings P. E.,Scott N. A. et al. Effects of gliclazide on platelet reactivity and free radicals in NIDDM patients: clinical assessment. Metabolism. 1992, v. 41 (suppl I), p. 36-39.</mixed-citation><mixed-citation xml:lang="en">Jennings P. E.,Scott N. A. et al. Effects of gliclazide on platelet reactivity and free radicals in NIDDM patients: clinical assessment. Metabolism. 1992, v. 41 (suppl I), p. 36-39.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Levy S. B. Platelets and diabetes mellitus. N Engl J Med, 1984, v.311, p. 665-667.</mixed-citation><mixed-citation xml:lang="en">Levy S. B. Platelets and diabetes mellitus. N Engl J Med, 1984, v.311, p. 665-667.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lyons T. J., Li W., Wells-Kneeht М. C., Jokl R. Toxicity of midly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes.</mixed-citation><mixed-citation xml:lang="en">Lyons T. J., Li W., Wells-Kneeht М. C., Jokl R. Toxicity of midly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Melander A., Bitsen P-О, Faber 0.,Groon L. Sulphonylurea antidiabetic drugs: an apdate of their clinical pharmacology and rational therapeutic use. Drugs, 1989, v. 37, p. 58-72.</mixed-citation><mixed-citation xml:lang="en">Melander A., Bitsen P-О, Faber 0.,Groon L. Sulphonylurea antidiabetic drugs: an apdate of their clinical pharmacology and rational therapeutic use. Drugs, 1989, v. 37, p. 58-72.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mullarkey C. J., Edelstein D., Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochim Biophys Res Commun, 1990, v 173,p. 932-939.</mixed-citation><mixed-citation xml:lang="en">Mullarkey C. J., Edelstein D., Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochim Biophys Res Commun, 1990, v 173,p. 932-939.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nakashima S., Tohmatsu T. et al. Inhibitory action of cGMP on secretion, phosphoinositide hydrolysis and calcium mobilization in trombin stimulated human platelets. Biochim Biophys Res Commun, 1986, v. 135,p. 1099-1 104.</mixed-citation><mixed-citation xml:lang="en">Nakashima S., Tohmatsu T. et al. Inhibitory action of cGMP on secretion, phosphoinositide hydrolysis and calcium mobilization in trombin stimulated human platelets. Biochim Biophys Res Commun, 1986, v. 135,p. 1099-1 104.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">O'Brien R. S., Luo M. Antioxidant properties of sulphonylureas. Diabetes 1996, v. 4S (suppl I), p. 36-39.</mixed-citation><mixed-citation xml:lang="en">O'Brien R. S., Luo M. Antioxidant properties of sulphonylureas. Diabetes 1996, v. 4S (suppl I), p. 36-39.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sage S. O., Merritt J. E., Hallam T. J., Rink T. J. Receptor-mediated calcium entry in fura-2-loaded human platelets with ADP and thrombin. Biochem J., 1989, v. 258, p. 923-926.</mixed-citation><mixed-citation xml:lang="en">Sage S. O., Merritt J. E., Hallam T. J., Rink T. J. Receptor-mediated calcium entry in fura-2-loaded human platelets with ADP and thrombin. Biochem J., 1989, v. 258, p. 923-926.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sang K-H. L. Q., Lantoine F., Devynck M-A. Influence of authentic nitric oxide on basal cytosolic (Ca++ )i and Ca++ release from internal stores in human platelets. Br J Pharmacol, 1996, v. 1 19, p. 1361 -1366.</mixed-citation><mixed-citation xml:lang="en">Sang K-H. L. Q., Lantoine F., Devynck M-A. Influence of authentic nitric oxide on basal cytosolic (Ca++ )i and Ca++ release from internal stores in human platelets. Br J Pharmacol, 1996, v. 1 19, p. 1361 -1366.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Schaeffer G., Wascher T. S., Kostner G. М., Graer W. F. Alterations in platelet Ca 2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia, 1999,v. 42,p. 167-176.</mixed-citation><mixed-citation xml:lang="en">Schaeffer G., Wascher T. S., Kostner G. М., Graer W. F. Alterations in platelet Ca 2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia, 1999,v. 42,p. 167-176.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Siess W. Molecular mechanisms of platelets activation. Physiol Rev 1989, v. 69, p.48-178.</mixed-citation><mixed-citation xml:lang="en">Siess W. Molecular mechanisms of platelets activation. Physiol Rev 1989, v. 69, p.48-178.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Trovati М., Massucco P., Mattiello L. The insulin-induced increase of guanosine-3, 5-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes, 1996, v. 45, p. 768-770.</mixed-citation><mixed-citation xml:lang="en">Trovati М., Massucco P., Mattiello L. The insulin-induced increase of guanosine-3, 5-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes, 1996, v. 45, p. 768-770.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
